Testosterone phenylacetate

Add links
Source: Wikipedia, the free encyclopedia.
Not to be confused with Testosterone phenylpropionate, Testosterone propionate, or Testosterone isobutyrate.
Testosterone phenylacetate
Clinical data
Trade namesPerandren, Androject
Other namesTPA
Routes of
administration		Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester
Identifiers
  • [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 2-phenylacetate
JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CC4=CC=CC=C4)CCC5=CC(=O)CC[C@]35C
  • InChI=1S/C27H34O3/c1-26-14-12-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)15-13-23(21)26)30-25(29)16-18-6-4-3-5-7-18/h3-7,17,21-24H,8-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1
  • Key:WIJSFCWRMNIREB-ZLQWOROUSA-N

Testosterone phenylacetate (TPA; brand names Perandren, Androject) is an

testosterone ester.[1][2][3] Analogously to estradiol benzoate having been one of the first estrogen esters to be introduced, testosterone phenylacetate was one of the first testosterone esters to be introduced.[4] However, since its introduction, it has largely been replaced by other esters, such as testosterone propionate.[4]

Testosterone phenylacetate was a 50 mg/mL

palliation of breast cancer in females.[8][9] It was developed by Ciba Pharmaceutical Company.[8]

A study found that, measured by

duration of any clinically used androgen marketed up to that point.[12]

Testosterone phenylacetate in aqueous suspension by intramuscular injection, similarly to other aqueous suspension formulations, causes local

oil solutions.[11] The injection site reactions were viewed as less important in the case of testosterone phenylacetate due to its prolonged duration and less frequent administration.[11]

See also

References

  1. ISBN 978-1-4757-2085-3
    .
  2. ISBN 978-3-88763-075-1
    .
  3. ISBN 978-94-011-4439-1
    .
  4. ^
    ISBN 978-0-470-01552-0
    .
  5. PMID 13849734
    .
  6. ^
    ISBN 9780870411236
    . Testosterone Phenylacetate (Perandren Phenyl- acetate®): This microcrystalline aqueous suspension for intramuscular use has a prolonged action similar to Depo-Testosterone®. It is supplied as 10 ml vials of 50 mg/ml. The average dose is 50-200 mg every 3-5 weeks.
  7. ^ Physicians Desk Reference to Pharmaceutical Specialties and Biologicals. Medical Economics. 1968. p. 624.
  8. ^ a b c Federal Register. Office of the Federal Register, National Archives and Records Service, General Services Administration. September 1977. pp. 52488–.
  9. ^
    ISBN 9780683002928
    .
  10. ^ Lisser H, Escamilla RF (1962). Atlas of Clinical Endocrinology. Mosby. Testosterone phenylacetate (Perandren phenylacetate)—Long-acting suspension of macrocrystals. Dose, 100 to 200 mg. intramuscularly every 2 to 4 weeks.
  11. ^
    S2CID 39965563
    .
  12. ^ Modern Drugs: The Journal of the Modern Drug Encyclopedia. Drug Publications. 1955.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Testosterone_phenylacetate&oldid=1215136187"